Navigation Links
MiMedx Reports On Meeting With FDA
Date:10/28/2013

MARIETTA, Ga., Oct. 28, 2013 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company concluded a productive meeting with the Food and Drug Administration ("FDA") earlier today, October 28, 2013.

Parker H. Petit, Chairman and CEO, said, "We were pleased to have had the opportunity to present to the FDA our basis for concluding that our micronized products are minimally manipulated and meet the criteria for regulation solely under Section 361 of the Public Health Service Act and 21 CFR 1271 of the FDA's regulations. The FDA acknowledged that our presentation included new information that they would review and consider, and they committed to responding in a timely fashion.  We hope that, upon further analysis, the FDA will agree with our position.  In all events, we are committed to continuing to work with the Agency to agree on a regulatory solution to ensure that our micronized products are available for patients who can benefit from their clinical effectiveness. These solutions could include, among other things, one or more of the following: labeling changes, changes to the product, changes to the process, or submission of a Biologics License Application." 

About MiMedx 
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies pr
'/>"/>

SOURCE MiMedx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
2. MiMedx Group Completes $5,000,000 Private Placement
3. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
4. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
5. MiMedx Group Announces 2011 Results
6. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
7. MiMedx Exceeds Revenue Goal for First Quarter of 2012
8. MiMedx Group Announces Record First Quarter Results
9. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
10. MiMedx Group Announces Record Second Quarter Results
11. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... DUBLIN , July 28, 2014 Research ... "Global Particle Size Analysis Market 2014-2018" report to their ... Particle size analysis is a technique used to determine ... powder or liquid. It is crucial to analyze the size ... material. Therefore, particle size analysis is performed to determine the ...
(Date:7/26/2014)... NY (PRWEB) July 26, 2014 ... provides key market data on the Canada Endoscopy ... millions of US dollars, volume (in units) and ... - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization ... Full Report at http://www.marketresearchreports.biz/analysis/213254 . , The ...
(Date:7/25/2014)... Amgen (NASDAQ: AMGN ) announced ... per share dividend for the third quarter of 2014. ... to all stockholders of record as of the close ... About Amgen Amgen is committed to unlocking the potential ... discovering, developing, manufacturing and delivering innovative human therapeutics. This ...
(Date:7/25/2014)... new study by researchers from the University of ... nanosystems function, unlocking the potential to create new ... which has been published in the prestigious academic ... novel laser technique to examine in rich detail ... small cluster containing an acetylene molecule and a ...
Breaking Biology Technology:Global Particle Size Analysis Market 2014-2018 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3
... Pharmaceuticals, a,division of Wyeth (NYSE: WYE ... for XYNTHA(TM) Antihemophilic Factor (Recombinant),Plasma/Albumin-Free, a new ... and prevention of bleeding episodes and surgical ... inherited blood-clotting disorder., XYNTHA is produced ...
... Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it ... trial using intravenous,administration of REOLYSIN(R) in combination with ... neck cancers. The Principal,Investigator is Dr. Monica Mita ... The University of Texas Health Science Center at ...
... Senior-friendly ,PlanPrescriber, Software Simplifies Medicare - For Free, ... today,announced the latest release of their PlanPrescriber tool. ... worry about whether they are,getting the most out ... MIT Professor Glen Urban, provides users with easy ...
Cached Biology Technology:New Recombinant XYNTHA Now Available for Patients with Hemophilia A 2New Recombinant XYNTHA Now Available for Patients with Hemophilia A 3New Recombinant XYNTHA Now Available for Patients with Hemophilia A 4New Recombinant XYNTHA Now Available for Patients with Hemophilia A 5Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3On-Line Medicare Advisor Saves Seniors Time, Hassle and Money 2
(Date:7/28/2014)... rat brain cells suggests that the effects of a ... cells are temporary. , The study, published in this ... was conducted by biologists at the University of California, ... York in response to concerns, arising from multiple studies ... to general anesthetics may increase their susceptibility to long-term ...
(Date:7/28/2014)... identified areas of the Earth that are high priorities ... Europe is particularly vulnerable, as it has the lowest ... of any continent in ,refugia, areas of biological ... remain relatively constant during times of great environmental change. ... in Scandinavia and Scotland. , The biggest refugia ...
(Date:7/28/2014)... advance the genetic engineering of "fuel" crops for ... by researchers with the U.S. Department of Energy ... led by Lawrence Berkeley National Laboratory (Berkeley Lab). ... enables scientists to identify and characterize the function ... biosynthesis of plant cell walls. , "Our unique ...
Breaking Biology News(10 mins):Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2How sweet it is 2How sweet it is 3
... , ASHEVILLE, NC A recent analysis of two ... (FIA) data shows the live volume of hemlocks in ... of hemlock woolly adelgid. FIA scientists from the Forest ... (NRS) published the information as an SRS e-Science Update ...
... laboratory mice have been widely used in research aimed at ... variations in past gene sequences of mice were unknown. While ... was in a certain region, they couldn,t pinpoint the exact ... new research recently published in the journal Nature , ...
... 2011Magnetic resonance tractography (MRT) is a valuable, noninvasive ... as MRT methods and technologies advance, has the ... brain activity and connectivity. Critical information about the ... in a forward-looking review article in the groundbreaking ...
Cached Biology News:Hemlocks still abundant despite adelgid infestations 2UCLA Engineering researchers help develop complete map of mouse genetic variation 2
... PhosphoPlus™ SAPK/JNK (Thr183/Tyr185) Antibody Kit ... Antibody, Catalog #9251, 200 ul SAPK/JNK ... ul SAPK/JNK Cell Extracts, Catalog #9253, ... Antibody, Catalog #7074, 100 ul Anti-biotin ...
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
...
Anti-human Carcinoma Associated Antigen, Clone 115D8, Monoclonal Antibody Innate Immunity - Tumor Markers...
Biology Products: